Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis

OBJECTIVE: The use of tenofovir (TDF) and entecavir (ETV) in patients with chronic hepatitis B (CHB) has led to a decrease in the incidence of hepatocellular carcinoma (HCC) and liver-related events. However, whether there is a difference between the two agents in the extent of improving such outcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sung Won, Kwon, Jung Hyun, Lee, Hae Lim, Yoo, Sun Hong, Nam, Hee Chul, Sung, Pil Soo, Nam, Soon Woo, Bae, Si Hyun, Choi, Jong Young, Yoon, Seung Kew, Han, Nam Ik, Jang, Jeong Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306978/
https://www.ncbi.nlm.nih.gov/pubmed/31672838
http://dx.doi.org/10.1136/gutjnl-2019-318947

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306978/
https://www.ncbi.nlm.nih.gov/pubmed/31672838
http://dx.doi.org/10.1136/gutjnl-2019-318947

Ejemplares similares